MEDIOCON INC – Lapaquistat Acetate, also known as TAK-475, is a synthetic small-molecule squalene synthase inhibitor that was investigated as a cholesterol-lowering agent. It acts on squalene synthase, an enzyme involved in the cholesterol biosynthesis pathway. Lapaquistat Acetate was investigated in clinical development for dyslipidemia and hypercholesterolemia.
Lapaquistat Acetate is a synthetic inhibitor of squalene synthase (farnesyl-diphosphate farnesyltransferase, FDFT1). Squalene synthase catalyzes the conversion of farnesyl pyrophosphate to squalene, a committed step in the biosynthesis of cholesterol.
By inhibiting this enzyme, Lapaquistat was investigated for its potential to reduce cholesterol synthesis and lower circulating lipid levels.
Product Name: Lapaquistat Acetate
CAS Number: 189060-13-7
Molecular Formula: C₃₃H₄₁ClN₂O₉
Molecular Weight: Approximately 645.14 g/mol
Chemical Class: Squalene synthase inhibitor
Synonyms: TAK-475, TAK475, TAK 475, Lapaquistat Acetate
PubChem CID: 9874248
UNII: IUH3AY74O3
NCI Code: C29703
Lapaquistat Acetate inhibits squalene synthase (FDFT1), an enzyme downstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. Squalene synthase catalyzes the dimerization of farnesyl pyrophosphate to form squalene.
Inhibition of this enzyme was investigated as a mechanism for reducing hepatic cholesterol biosynthesis and consequently lowering cholesterol levels.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Lapaquistat Acetate quality evaluation may include identity, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Lapaquistat Acetate was investigated as a cholesterol-lowering agent for dyslipidemia and hypercholesterolemia. Clinical development included studies evaluating its use alone and in combination with statin therapy.
Development of lapaquistat was discontinued following safety concerns, including potential hepatic toxicity. Therefore, it should be described as an investigational/discontinued-development compound rather than a currently approved cholesterol-lowering medicine.
Lapaquistat Acetate is a defined synthetic small molecule with molecular formula C₃₃H₄₁ClN₂O₉ and molecular weight approximately 645.14 g/mol.
The compound is identified by CAS 189060-13-7 and is structurally related to lapaquistat, which has CAS 189059-71-0 and molecular weight approximately 603.1 g/mol.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lapaquistat Acetate API Manufacturer and Supplier in India (CAS 189060-13-7) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Lapaquistat Acetate API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance